Skip to main content

Advertisement

SpringerLink
Log in

Correlation of p53 Status with the Response to Chemotherapy-Based Treatment in Esophageal Cancer: A Meta-Analysis

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The value of p53 status for predicting response to chemotherapy-based treatment in patients with esophageal cancer has been controversial. We conducted a meta-analysis to elucidate the correlation of p53 status with the response to chemotherapy-based treatment.

Methods

Studies were searched in PubMed, Embase, and Web of Science (up to September 2012). The p53 status and response to therapy were defined and standardized. Subgroup analyses based on the treatment and histopathology were performed to explore the usefulness of p53 status for predicting response to therapy in esophageal cancer. Sensitivity analyses were conducted by removing specific studies to assess the effects of study quality.

Results

We included 28 studies with 1497 cases in our meta-analysis. Wild-type form of p53 status (low expression of p53 protein and/or wild-type p53 gene) was associated with high response to chemotherapy-based treatment in esophageal cancer (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03–1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06–1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00–1.17, P = .040). The similar correlation between the wild-type form p53 and response to therapy were also detected in subgroup analyses (total MR, pathological MR, and total CR in chemoradiotherapy subgroup; total MR in chemotherapy subgroup; total MR and pathological CR in esophageal squamous cell carcinoma [ESCC]). Additionally, patients with wild-type form p53 status had high pathological complete response rate to neoadjuvant chemoradiotherapy in ESCC.

Conclusions

The current meta-analysis suggested that p53 status might be a predictive biomarker for response to chemotherapy-based treatment in esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.

    Article  PubMed  CAS  Google Scholar 

  3. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.

    Article  PubMed  Google Scholar 

  4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  PubMed  Google Scholar 

  5. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet Oncol. 2002;359:1727–33.

    Article  Google Scholar 

  6. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.

    Article  PubMed  Google Scholar 

  7. Brucher BL, Stein HJ, Zimmerman F, Werner M, Sarbia M, Busch R, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963–71.

    PubMed  CAS  Google Scholar 

  8. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127–43.

    Article  PubMed  CAS  Google Scholar 

  9. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804–11.

    Article  PubMed  Google Scholar 

  10. Lam KY. Tsao SW, Zahng D, Law S, He D, Ma L, et al. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: prospective clinico-pathological study and survival analysis of 70 patients. Int J Cancer. 1997;74:212–9.

    Article  PubMed  CAS  Google Scholar 

  11. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;37:413–31.

    Article  Google Scholar 

  12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–10.

    Article  PubMed  CAS  Google Scholar 

  13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–67.

    Article  PubMed  CAS  Google Scholar 

  14. Levine AJ. p53, cellular gatekeeper for growth and division. Cell. 1997;88:323–31.

    Article  PubMed  CAS  Google Scholar 

  15. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998;292:435–45.

    Article  PubMed  CAS  Google Scholar 

  16. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2009;17:804–11.

    Article  PubMed  Google Scholar 

  17. Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, et al. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2010;17:634–42.

    Article  PubMed  Google Scholar 

  18. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:284–9.

    PubMed  CAS  Google Scholar 

  19. Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol. 1999;12:251–6.

    PubMed  CAS  Google Scholar 

  20. Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J Gastroenterol. 2005;11:5696–700.

    PubMed  CAS  Google Scholar 

  21. Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol. 2012;19:757–65.

    Article  PubMed  Google Scholar 

  22. Kishi K, Doki Y, Yano M, Yasuda T, Fujiwara Y, Takiguchi S, et al. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003;9:4368–75.

    PubMed  CAS  Google Scholar 

  23. Fukuchi M, Fukai Y, Sohda M, Miyazaki T, Nakajima M, Inose T, et al. Expression of the prolyl isomerase Pin1 is a useful indicator of sensitivity to chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncology Rep. 2009;21:853–9.

    CAS  Google Scholar 

  24. Nam TK, Lee JH, Cho SH, Chung IJ, Ahn SJ, Song JY, et al. Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett. 2008;260:109–17.

    Article  PubMed  CAS  Google Scholar 

  25. Sarbia M, Ott N, Pühringer-Oppermann F, Brücher BLDM. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer. 2007;97:1404–8.

    Article  PubMed  CAS  Google Scholar 

  26. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110:838–44.

    Article  PubMed  CAS  Google Scholar 

  27. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res. 2004;10:6208–14.

    Article  PubMed  CAS  Google Scholar 

  28. Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol. 1994;172:1–4.

    Article  PubMed  CAS  Google Scholar 

  29. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.

    PubMed  CAS  Google Scholar 

  30. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–40.

    Article  PubMed  CAS  Google Scholar 

  31. Japanese Society for Esophageal Diseases. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th ed. Tokyo: Kanehara & Co, Ltd; 1999.

  32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  33. Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for ESCC. J Clin Pathol. 1996;49:456–9.

    Article  PubMed  CAS  Google Scholar 

  34. Muro K, Ohtsu A, Boku N, Chin K, Oda Y, Fujii T, et al. Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 1996;26:65–9.

    Article  PubMed  CAS  Google Scholar 

  35. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, et al. P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg. 1999;68:2021–5.

    Article  PubMed  CAS  Google Scholar 

  36. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 1999;19:5515–21.

    PubMed  CAS  Google Scholar 

  37. Shimada Y, Watanabe G, Yamasaki S, Maeda M, Kawabe A, Kaganoi JI, et al. Histological response of cisplatin predicts patients’ survival in oesophageal cancer and p53 protein accumulation. Eur J Cancer. 2000;36:987–93.

    Article  PubMed  CAS  Google Scholar 

  38. Szumilo J, Chibowski D, D browski A. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy. Dis Esophagus. 2000;13:191–7.

    Article  PubMed  CAS  Google Scholar 

  39. Takeno S, Noguchi T, Takahashi, Kikuchi R, Uchida Y, Yokoyama S. Immunohistochemical and clinicopathologic analysis of response to neoadjuvant therapy for esophageal squamous cell carcinoma. Dis Esophagus. 2001;14:149–54.

    Article  PubMed  CAS  Google Scholar 

  40. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol. 2001;36:303–11.

    Article  PubMed  CAS  Google Scholar 

  41. Kajiyama Y, Hattori K, Tomita N, Amano T, Iwanuma Y, Narumi K, et al. Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus multivariate analysis of predictive factors and p53 overexpression. Dis Esophagus. 2002;15:61–6.

    Article  PubMed  CAS  Google Scholar 

  42. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002;86:552–7.

    Article  PubMed  CAS  Google Scholar 

  43. Michel P, Magois K, Robert V, Chiron A, Lepessot F, Bodenant C, et al. Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:379–85.

    Article  PubMed  CAS  Google Scholar 

  44. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer predictors of response to neoadjuvant therapy. J Gastrointest Surg. 2003;7:77–87.

    Article  PubMed  Google Scholar 

  45. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2003;10:792–800.

    Article  PubMed  Google Scholar 

  46. Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res. 2004;24:2579–83.

    PubMed  Google Scholar 

  47. Nakamura T, Hayashi K, Ota, M, Ide H, Takasaki K, Mitsuhashi M. Expression of p21 predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus. 2004;17:315–21.

    Article  PubMed  CAS  Google Scholar 

  48. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, et al. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 2005;25:2749–55.

    PubMed  Google Scholar 

  49. Ishida M, Morita M, Saeki H, Ohga T, Sadanaga N, Watanabe M, et al. Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer Res. 2007;27:3501–6.

    PubMed  CAS  Google Scholar 

  50. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–9.

    Article  PubMed  CAS  Google Scholar 

  51. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165–74.

    Article  PubMed  CAS  Google Scholar 

  52. Nasierowska-Guttmejer A, Szawlowski AW, Falkowski S, Morysinski T. Histopathological evaluation of response to pre-operative concurrent chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 1995;8:136–41.

    Google Scholar 

Download references

Acknowledgements

This work was supported by of Chinese Ministry of Health Key Program grant (No. 179). We would like to thank the authors of the studies included in our manuscript.

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

    Shui-Shen Zhang MD, Qing-Yuan Huang MD, Hong Yang MD, Xuan Xie MD, Kong-Jia Luo MD, PhD, Jing Wen MD, PhD, Fu Yang MD, Yi Hu MD, PhD & Jian-Hua Fu MD, PhD

  2. Guangdong Esophageal Cancer Research Institute, Guangzhou, People’s Republic of China

    Shui-Shen Zhang MD, Qing-Yuan Huang MD, Hong Yang MD, Xuan Xie MD, Kong-Jia Luo MD, PhD, Jing Wen MD, PhD, Fu Yang MD, Yi Hu MD, PhD & Jian-Hua Fu MD, PhD

  3. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

    Shui-Shen Zhang MD, Qing-Yuan Huang MD, Hong Yang MD, Xuan Xie MD, Kong-Jia Luo MD, PhD, Jing Wen MD, PhD, Fu Yang MD, Yi Hu MD, PhD & Jian-Hua Fu MD, PhD

  4. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China

    Xiao-Li Cai MD

Authors
  1. Shui-Shen Zhang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing-Yuan Huang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuan Xie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kong-Jia Luo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing Wen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-Li Cai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fu Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi Hu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jian-Hua Fu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-Hua Fu MD, PhD.

Additional information

Shui-Shen Zhang and Qing-Yuan Huang contributed equally to this work and share first authorship.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 28 kb)

10434_2012_2859_MOESM2_ESM.tif

Supplement Figure 1: Forest plots of RR were estimated for association between p53 status and pathological complete response (CR) to neoadjuvant chemoradiotherapy (NCRT) in patients with esophageal squamous cell carcinoma. Supplementary material 2 (TIFF 53 kb)

10434_2012_2859_MOESM3_ESM.tif

Supplement Figure 2: The funnel plot shows that there was no obvious indication of publication bias for the outcome of total major response (MR) to chemotherapy-based treatment in patients with esophageal cancer. Supplementary material 3 (TIFF 66 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, SS., Huang, QY., Yang, H. et al. Correlation of p53 Status with the Response to Chemotherapy-Based Treatment in Esophageal Cancer: A Meta-Analysis. Ann Surg Oncol 20, 2419–2427 (2013). https://doi.org/10.1245/s10434-012-2859-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2859-4

Keywords

Search

Navigation